Europe Chemiluminescence Immunoassay Market Size 2023 | Industry Analysis by Trends, Future Demands, Top Key Players & Forecast till 2028

According to a recent report by MarketsandMarkets™, The Global Chemiluminescence Immunoassay Market is projected to exhibit significant growth in the coming years. The market’s revenue was estimated to be $13.2 billion in 2023 and is poised to reach $19.0 billion by 2028, with a compound annual growth rate (CAGR) of 7.5% from 2023 to 2028.

The market’s growth is primarily attributed to several factors. Firstly, the increasing prevalence of chronic diseases has created a higher demand for diagnostic techniques, including chemiluminescence immunoassays. These assays offer sensitive and accurate detection of biomarkers, aiding in disease diagnosis and monitoring.

Furthermore, advancements in chemiluminescence immunoassay technologies have greatly improved their performance and efficiency. Ongoing research and development efforts have resulted in enhanced sensitivity, specificity, and multiplexing capabilities, further driving the market growth.

Download an Illustrative overview:

The rising demand for point-of-care testing (POCT) is another significant factor contributing to market expansion. Chemiluminescence immunoassay systems are increasingly being adopted for POCT due to their rapid and reliable results, enabling efficient patient management and treatment decisions.

The growth of the biotechnology and biopharmaceutical industries also plays a role in driving the chemiluminescence immunoassay market. These industries heavily rely on immunoassay techniques for drug discovery, development, and monitoring, leading to increased adoption of chemiluminescence immunoassay systems.

Browse in-depth TOC on “Chemiluminescence Immunoassay Market”

181 – Tables
52 – Figures
283 – Pages

The chemiluminescence immunoassay market is segmented based on product and application. In terms of product, the market is categorized into consumables and instruments. In 2022, the consumables segment held the largest share of the market.

The consumables segment’s dominance can be attributed to several factors. One key factor is the repetitive purchase of consumables such as reagents for every test. As chemiluminescence immunoassay tests are performed regularly in clinical settings, the demand for consumables remains high, contributing to the growth of this segment.

Additionally, the availability of efficient assays and reagents for diagnostic purposes has significantly propelled the demand for consumables. These consumables play a vital role in facilitating accurate and reliable results in chemiluminescence immunoassay tests, further driving their adoption among end users.

On the other hand, the chemiluminescence immunoassay market’s application segment includes various categories such as infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, gastroenterology, neurology, respiratory, therapeutic drug monitoring, metabolic disorders, and other applications.

In 2022, the infectious disease diagnostics segment held the largest share in the chemiluminescence immunoassay market in terms of application. This significant market share can be attributed to multiple factors. Firstly, there has been a notable development and introduction of advanced assays specifically designed for the diagnosis of different infectious diseases. These assays provide rapid and accurate results, contributing to their widespread adoption.

Additionally, the global population affected by infectious diseases has been increasing, creating a higher demand for effective diagnostic tools. Chemiluminescence immunoassays offer sensitive and specific detection of infectious disease biomarkers, aiding in early diagnosis and prompt treatment.

North America dominates the global chemiluminescence immunoassay market

Based on the region, the chemiluminescence immunoassay market is segmented into North America, Europe, Asia Pacific, and Rest of the world. In 2022, North America accounted for the largest share of the chemiluminescence immunoassay market. The large share of North America in this market can be attributed to the increasing prevalence of infectious diseases and cancer and rising healthcare spending, which is highly developed in the US and Canada.

Report Sample Report:

Chemiluminescence Immunoassay Market Dynamics:


  1. Rising incidence of chronic and infectious diseases across the globe


  1. High cost of CLIA related products


  1. Increasing number of collaborations and partnerships in the CLIA market


  1. Lack of skilled professionals and aging workforce

Key Market Players:

The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Siemens Healthineers AG (Germany), DiaSorin S.p.A. (Italy), Abbott Laboratories (US), Shenzhen Mindray Bio-medical Electronics Co., Ltd. (China), Sysmex Corporation (Japan), Diatron (Hungary), Getein Biotech, Inc. (China), Werfen (Spain), QuidelOrtho Corporation (US), EUROIMMUN (Germany), Merck KGaA (Germany), Tosoh Corporation (Japan), Trivitron Healthcare (India), Abnova Corporation (Taiwan), Elabscience (US), Maccura Biotechnology Co., Ltd. (China), Autobio Diagnostics Co., Ltd. (China), Jiangsu Zecen Biotech Co., Ltd (China), Rayto Life and Analytical Sciences Co., Ltd. (China), Daan Gene Co., Ltd. (China), DYNEX TECHNOLOGIES, Inc. (US), Zybio, Inc. (China), Wiener Laboratorios SAIC (Argentina), Tianjin Era Biology Technology Co., Ltd. (China).

Recent Developments:

  • In May 2023, EUROIMMUN’s parent company PerkinElmer’s life science and diagnostics business segment, has been rebranded as Revvity.
  • In December 2022, Mindray launched CLIA-based assays, IL-6, PCT, and sCD14-S, which have high sensitivity, a wide linearity range, great precision, and good anti-interference ability.
  • In December 2022, Sysmex received manufacturing and marketing approval in Japan for the HISCL β-Amyloid 1-42 Assay Kit and the HISCL β-Amyloid 1-40 Assay Kit to measure amyloid beta (Aβ) in the blood.
  • In November 2022 Getein Biotech, Inc. launched MAGICL 6000, a compact and innovative chemiluminescence immunoassay analyzer used in mid to high-workflow laboratories
  • In June 2022, QuidelOrtho Corporation was formed through a transaction between Quidel Corporation and Ortho Clinical Diagnostics to form a leading in vitro diagnostics company.

Get 10% Free Customization on this Report:

Chemiluminescence Immunoassay Market Advantages:

  • Sensitivity and Specificity: Chemiluminescence immunoassays provide high sensitivity and specificity in detecting target molecules. The use of specific antibodies and the amplification of chemiluminescent signals result in low detection limits and minimal interference from background noise, ensuring accurate and reliable results.
  • Wide Analyte Range: Chemiluminescence immunoassays can detect a diverse range of analytes, including proteins, hormones, tumor markers, infectious agents, and drugs. This versatility allows for comprehensive testing across various applications, including clinical diagnostics, pharmaceutical research, environmental monitoring, and food safety.
  • Multiplexing Capabilities: Chemiluminescence immunoassays enable multiplexing, the simultaneous detection of multiple analytes in a single assay. This capability is particularly valuable in clinical diagnostics, where it allows for the efficient and cost-effective assessment of multiple biomarkers, aiding in disease diagnosis, prognosis, and treatment monitoring.

Speed and Automation: Chemiluminescence immunoassays offer rapid results due to the short incubation times required for chemiluminescent reactions. Additionally, the integration of automated systems and robotic platforms streamlines the workflow, reducing manual handling and increasing throughput. This combination of speed and automation enhances laboratory efficiency and productivity.